Today: 22 June 2026

Khadija Saeed

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

QuantumScape Stock Jumps Toward $8 as Battery Bet Faces Its Big 2026 Test

QuantumScape Stock Jumps Toward $8 as Battery Bet Faces Its Big 2026 Test

QuantumScape shares rose to $7.95 Wednesday, up 70 cents, after the company said it began producing initial volumes of QSE-5 solid-state battery cells at its new Eagle Line pilot facility in San Jose. The company reported a first-quarter net loss of $100.8 million and said it has not yet generated revenue from principal operations. QuantumScape continues to work with Volkswagen Group’s PowerCo and other major automakers on testing.
Alaska Air’s $500 Million Debt Sale Shows How Iran War Fuel Shock Is Hitting U.S. Airlines

Alaska Air’s $500 Million Debt Sale Shows How Iran War Fuel Shock Is Hitting U.S. Airlines

Alaska Air Group launched a $500 million private debt offering Wednesday as jet fuel prices nearly doubled following U.S.-Israeli strikes against Iran. The five-year senior notes, due 2031, will help offset surging costs that forced Alaska to withdraw its profit forecast last month. American Airlines and JetBlue also raised debt recently to manage higher fuel bills.
DoorDash Stock Jumps After Order Forecast Beats Wall Street, Even as Profit Slips

DoorDash Stock Jumps After Order Forecast Beats Wall Street, Even as Profit Slips

DoorDash shares jumped 10% after the company forecast second-quarter marketplace gross order value of $32.4–$33.4 billion, above analyst estimates. First-quarter orders rose 27% to 933 million, with GOV up 37% to $31.6 billion and revenue up 33% to $4.036 billion. Net income fell 5% to $184 million. DoorDash expects its Dasher gas relief program to cost over $50 million in Q2.
Axon Stock: Q1 Revenue Jumps 34% as AI and Drone Demand Lift 2026 Outlook

Axon Stock: Q1 Revenue Jumps 34% as AI and Drone Demand Lift 2026 Outlook

Axon reported first-quarter revenue of $807 million, up 34% and above analyst estimates, driven by strong demand for police software, Tasers, body cameras, and AI products. The company raised its 2026 revenue growth forecast to 30%–32%. Software and services revenue climbed 35% to $355 million, while AI product revenue surged over 700%. Gross margin fell to 59.1% due to tariffs and Dedrone-related costs.
Snap Stock Slides After Q1 Revenue Jump As Perplexity Deal Ends And Guidance Stays Cautious

Snap Stock Slides After Q1 Revenue Jump As Perplexity Deal Ends And Guidance Stays Cautious

Snap Inc. reported first-quarter revenue up 12% to $1.53 billion and daily active users rising to 483 million, but shares fell 5% in late trading after a cautious second-quarter forecast and the end of its $400 million Perplexity AI deal. Net loss narrowed to $89 million. North America user numbers and revenue growth remained weak. The company cited Middle East uncertainty as a near-term drag.
Coherent Stock Falls After AI-Fueled Q3 Beat: Why Wall Street Still Sold COHR

Coherent Stock Falls After AI-Fueled Q3 Beat: Why Wall Street Still Sold COHR

Coherent Corp. shares dropped about 6% in late trading Wednesday despite reporting fiscal Q3 revenue of $1.81 billion, up 20.5% year-over-year and above estimates. Datacenter & Communications revenue rose sharply to $1.36 billion, while Industrial revenue fell. Adjusted operating income missed expectations, and free cash flow was negative $536.9 million. The company forecast stronger-than-expected Q4 revenue and earnings.
AppLovin Stock Drops After Q1 Earnings Beat as Wall Street Questions What Comes Next

AppLovin Stock Drops After Q1 Earnings Beat as Wall Street Questions What Comes Next

AppLovin reported first-quarter revenue of $1.84 billion, up 59% year-over-year, and net income of $1.21 billion, more than double last year’s figure. Shares fell 2.3% in after-hours trading despite the company forecasting second-quarter revenue above analyst estimates. Adjusted EBITDA margin rose to 85%. AppLovin repurchased 2.2 million shares for $1 billion during the quarter.
This Is Why Loblaw Stock Fell Even as Profit Rose

This Is Why Loblaw Stock Fell Even as Profit Rose

Loblaw missed first-quarter revenue estimates, posting C$14.48 billion versus the expected C$14.55 billion, sending shares down 5%. Net earnings rose to C$594 million, and the company raised its dividend by 10% while approving a new buyback. Discount banners No Frills and Maxi drove growth as shoppers continued to trade down.
6 May 2026
Celsius Stock Near 52-Week Low Before Q1 Earnings as PepsiCo Energy Bet Faces Test

Celsius Stock Near 52-Week Low Before Q1 Earnings as PepsiCo Energy Bet Faces Test

Celsius Holdings shares traded near a 52-week low Wednesday ahead of its first-quarter earnings report, as investors awaited signs of growth from its expanded portfolio with PepsiCo. The company will release results before markets open Thursday. Analysts expect Q1 revenue of $755.2 million, up 129% year-over-year. Celsius now manages CELSIUS, Alani Nu, and Rockstar Energy in the U.S. and Canada.
Beyond Meat Stock Reclaims $1 Before BYND Earnings, But Nasdaq Pressure Remains

Beyond Meat Stock Reclaims $1 Before BYND Earnings, But Nasdaq Pressure Remains

Beyond Meat shares rose above $1 to $1.02 Wednesday ahead of first-quarter earnings, after closing below that level Tuesday. The company faces Nasdaq delisting if its bid price does not stay at or above $1 for 10 straight business days by Aug. 31. Beyond guided Q1 net revenue to $57–$59 million, down from $61.6 million in Q4. U.S. plant-based meat sales remain weak, pressuring the company’s turnaround efforts.
Compass Stock Jumps 26% After Anywhere Deal Fuels Profit, Strong Q2 Outlook

Compass Stock Jumps 26% After Anywhere Deal Fuels Profit, Strong Q2 Outlook

Compass Inc. shares surged 26% after posting a first-quarter profit and forecasting second-quarter revenue above Wall Street estimates. Revenue nearly doubled to $2.70 billion, boosted by the Anywhere Real Estate acquisition. The company reported GAAP net income of $22 million, compared to a $51 million loss a year ago. Compass raised its cost-saving targets and said brokerage transaction value reached $97.3 billion.
Bayer’s $2.45 Billion Perfuse Deal Puts Eye-Drug Pipeline Back in Focus

Bayer’s $2.45 Billion Perfuse Deal Puts Eye-Drug Pipeline Back in Focus

Bayer agreed to acquire Perfuse Therapeutics for up to $2.45 billion, including $300 million upfront, to gain access to a mid-stage eye-disease drug, PER-001. Eylea, Bayer’s top-selling eye drug, saw 2025 sales fall 5.9% to €3.11 billion amid generic competition. The deal awaits antitrust and shareholder approval. PER-001 is in Phase II trials for glaucoma and diabetic retinopathy.
NICE Stock Tumbles After an Earnings Beat. The Guidance Is Why

NICE Stock Tumbles After an Earnings Beat. The Guidance Is Why

NICE Ltd. shares fell 22.9% to $96.35 after the company forecast second-quarter revenue below Wall Street estimates. First-quarter revenue and earnings beat expectations, with cloud revenue up 14.6% and AI annual recurring revenue up 66%. GAAP net income dropped to $46.8 million from $129.3 million a year earlier. NICE cited timing effects from large customer renewals as a factor in the outlook.
NANO Nuclear Stock Jumps as Supermicro AI Data Center Pact Puts Microreactors in Play

NANO Nuclear Stock Jumps as Supermicro AI Data Center Pact Puts Microreactors in Play

NANO Nuclear Energy signed a non-binding MOU with Super Micro Computer to explore using microreactors for powering AI data centers. NANO shares surged 24.6% and Supermicro rose 21.4% after the announcement and a strong outlook. No final contracts or reactor approvals were disclosed. NANO has not reported material revenue and remains in early development.
Why Ernexa Therapeutics Stock Jumped After ERNA-101 Ovarian Cancer Survival Data

Why Ernexa Therapeutics Stock Jumped After ERNA-101 Ovarian Cancer Survival Data

Ernexa Therapeutics said its ERNA-101 cell therapy plus PD-1 blockade cleared tumors and achieved 100% long-term survival in preclinical ovarian cancer models. Shares jumped about 60% after the announcement, trading between $3.70 and $7.66. The company remains preclinical and recently completed a 1-for-25 reverse stock split to maintain its Nasdaq listing.
Dell Technologies Stock Jumps As AI Server Rally And Texas Move Put June Vote In Focus

Dell Technologies Stock Jumps As AI Server Rally And Texas Move Put June Vote In Focus

Dell shares rose about 10% Wednesday, reaching $238.84, as demand for AI servers boosted the stock. The company will ask shareholders to approve moving its legal home from Delaware to Texas at its June 25 annual meeting. Michael Dell and Silver Lake hold enough voting power to influence the outcome. Dell’s market value stood at roughly $158.3 billion in afternoon trading.
CDW Corporation Stock Plunges 20% After Revenue Beat Exposes AI Margin Squeeze

CDW Corporation Stock Plunges 20% After Revenue Beat Exposes AI Margin Squeeze

CDW shares fell 19.5% intraday after first-quarter gross margin dropped to 21.0% from 21.6%, despite net sales rising 9.2% to $5.68 billion. Adjusted earnings of $2.28 per share missed analysts’ estimates by one cent. Investors focused on a shift toward lower-margin hardware sales. The stock traded at $110.11, down $26.69 from Tuesday’s close.
Joby Aviation Stock Jumps 18% After Q1 Earnings as Air Taxi Launch Hopes Take Over

Joby Aviation Stock Jumps 18% After Q1 Earnings as Air Taxi Launch Hopes Take Over

Joby Aviation shares surged 18% after first-quarter revenue beat expectations and the company reiterated plans for initial passenger flights in 2026. Joby ended March with $2.5 billion in cash and short-term investments. Net loss for the quarter was $110 million, with operating expenses at $258 million. FAA certification remains pending before broad commercial service can begin.
Novavax Stock Jumps as Pfizer Vaccine Deal Drives Big Q1 Revenue Beat

Novavax Stock Jumps as Pfizer Vaccine Deal Drives Big Q1 Revenue Beat

Novavax reported first-quarter revenue of $139.5 million, beating estimates as licensing and partner payments, including $30 million from Pfizer, offset weak COVID-19 vaccine sales. Shares rose 15.6% to $9.36 in afternoon trading. Product sales dropped to $42.2 million from $621.7 million a year ago. The company maintained its 2026 adjusted revenue forecast of $230 million to $270 million.
1 88 89 90 91 92 872

Stock Market Today

  • Capital Power (TSX:CPX) Shares Seen 42% Undervalued Following Julie Sloat Board Appointment
    June 22, 2026, 3:47 AM EDT. Capital Power (TSX:CPX) stock is gaining attention after Julie Sloat joined its Board of Directors, spotlighting governance amid share price gains. The stock has risen 15.05% over 30 days and 22.02% year to date, trading near its 52-week high. Analysts forecast 3.7% annual revenue growth and profit margins expanding from 0.6% to 13.3% in three years. Despite a last close of CA$73.53, the fair value is estimated at CA$74.42, implying a 42% undervaluation based on long-term cash flow models. Risks include potential electricity demand shortfalls and high financing costs. Investors are advised to review forecasts and monitor key risks while considering broader market opportunities.

Latest articles

Cognizant (NASDAQ: CTSH) Slides 10% as Nasdaq-100 Exit Nears

Cognizant (NASDAQ: CTSH) Slides 10% as Nasdaq-100 Exit Nears

22 June 2026
Cognizant shares plunged 10.49% to $43.70, erasing $2.4 billion in equity value—more than its $2 billion 2026 buyback target—after Accenture’s narrowed growth outlook, a Berenberg downgrade, and looming Nasdaq-100 removal, even as S&P 500 and Nasdaq rallied; investors now eye Q2 guidance as the next key test.
Pentagon Could Outpace Tech Giants on Small Nuclear Projects

Pentagon Could Outpace Tech Giants on Small Nuclear Projects

22 June 2026
Valar Atomics’ Ward 250 became the first DOE-authorized advanced reactor built outside a national lab to achieve criticality, signaling a shift as U.S. defense demand accelerates small nuclear deployment, with the Army allocating over $2 billion for microreactors—moving the sector from policy to production and raising near-term demand expectations.
Go toTop